156 related articles for article (PubMed ID: 38435053)
1. Mechanism of drug resistance in HIV-1 protease subtype C in the presence of Atazanavir.
Sankaran SV; Krishnan SR; Sayed Y; Gromiha MM
Curr Res Struct Biol; 2024; 7():100132. PubMed ID: 38435053
[TBL] [Abstract][Full Text] [Related]
2. Understanding Drug Resistance of Wild-Type and L38HL Insertion Mutant of HIV-1 C Protease to Saquinavir.
Venkatachalam S; Murlidharan N; Krishnan SR; Ramakrishnan C; Setshedi M; Pandian R; Barh D; Tiwari S; Azevedo V; Sayed Y; Gromiha MM
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833460
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics and ligand docking of a hinge region variant of South African HIV-1 subtype C protease.
Zondagh J; Balakrishnan V; Achilonu I; Dirr HW; Sayed Y
J Mol Graph Model; 2018 Jun; 82():1-11. PubMed ID: 29625416
[TBL] [Abstract][Full Text] [Related]
4. Cantilever-centric mechanism of cooperative non-active site mutations in HIV protease: Implications for flap dynamics.
Sherry D; Worth R; Ismail ZS; Sayed Y
J Mol Graph Model; 2021 Jul; 106():107931. PubMed ID: 34030114
[TBL] [Abstract][Full Text] [Related]
5. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
Gupta A; Jamal S; Goyal S; Jain R; Wahi D; Grover A
BMC Bioinformatics; 2015; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
[TBL] [Abstract][Full Text] [Related]
6. HIV Protease Hinge Region Insertions at Codon 38 Affect Enzyme Kinetics, Conformational Stability and Dynamics.
Sheik Ismail Z; Worth R; Mosebi S; Sayed Y
Protein J; 2023 Oct; 42(5):490-501. PubMed ID: 37421557
[TBL] [Abstract][Full Text] [Related]
7. Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
Karnati KR; Wang Y
J Mol Graph Model; 2019 Nov; 92():112-122. PubMed ID: 31351319
[TBL] [Abstract][Full Text] [Related]
8. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
C S V; Tamizhselvi R; Munusami P
J Biomol Struct Dyn; 2019 Jul; 37(10):2608-2626. PubMed ID: 30051758
[TBL] [Abstract][Full Text] [Related]
9. Structural and thermodynamic basis of amprenavir/darunavir and atazanavir resistance in HIV-1 protease with mutations at residue 50.
Mittal S; Bandaranayake RM; King NM; Prabu-Jeyabalan M; Nalam MN; Nalivaika EA; Yilmaz NK; Schiffer CA
J Virol; 2013 Apr; 87(8):4176-84. PubMed ID: 23365446
[TBL] [Abstract][Full Text] [Related]
10. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
[TBL] [Abstract][Full Text] [Related]
11. Multi-drug resistance profile of PR20 HIV-1 protease is attributed to distorted conformational and drug binding landscape: molecular dynamics insights.
Chetty S; Bhakat S; Martin AJ; Soliman ME
J Biomol Struct Dyn; 2016; 34(1):135-51. PubMed ID: 25671669
[TBL] [Abstract][Full Text] [Related]
12. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
Vasavi CS; Tamizhselvi R; Munusami P
J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
[TBL] [Abstract][Full Text] [Related]
13. Exploring the potency of currently used drugs against HIV-1 protease of subtype D variant by using multiscale simulations.
Sk MF; Roy R; Kar P
J Biomol Struct Dyn; 2021 Feb; 39(3):988-1003. PubMed ID: 32000612
[TBL] [Abstract][Full Text] [Related]
14. Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations.
C S V; Munusami P
J Biomol Struct Dyn; 2023 Feb; 41(3):1000-1017. PubMed ID: 34919029
[TBL] [Abstract][Full Text] [Related]
15. Herb-drug interaction between an anti-HIV Chinese herbal SH formula and atazanavir in vitro and in vivo.
Cheng BH; Zhou X; Wang Y; Chan JY; Lin HQ; Or PM; Wan DC; Leung PC; Fung KP; Wang YF; Lau CB
J Ethnopharmacol; 2015 Mar; 162():369-76. PubMed ID: 25614104
[TBL] [Abstract][Full Text] [Related]
16. A molecular dynamics study comparing a wild-type with a multiple drug resistant HIV protease: differences in flap and aspartate 25 cavity dimensions.
Seibold SA; Cukier RI
Proteins; 2007 Nov; 69(3):551-65. PubMed ID: 17623840
[TBL] [Abstract][Full Text] [Related]
17. Drug Resistance Mechanism of M46I-Mutation-Induced Saquinavir Resistance in HIV-1 Protease Using Molecular Dynamics Simulation and Binding Energy Calculation.
Rana N; Singh AK; Shuaib M; Gupta S; Habiballah MM; Alkhanani MF; Haque S; Reshi MS; Kumar S
Viruses; 2022 Mar; 14(4):. PubMed ID: 35458427
[TBL] [Abstract][Full Text] [Related]
18. How Mutations Can Resist Drug Binding yet Keep HIV-1 Protease Functional.
Appadurai R; Senapati S
Biochemistry; 2017 Jun; 56(23):2907-2920. PubMed ID: 28505418
[TBL] [Abstract][Full Text] [Related]
19. Studies on adaptability of binding residues and flap region of TMC-114 resistance HIV-1 protease mutants.
Purohit R; Rajendran V; Sethumadhavan R
J Biomol Struct Dyn; 2011 Aug; 29(1):137-52. PubMed ID: 21696230
[TBL] [Abstract][Full Text] [Related]
20. Structural insights into the South African HIV-1 subtype C protease: impact of hinge region dynamics and flap flexibility in drug resistance.
Naicker P; Achilonu I; Fanucchi S; Fernandes M; Ibrahim MA; Dirr HW; Soliman ME; Sayed Y
J Biomol Struct Dyn; 2013 Dec; 31(12):1370-80. PubMed ID: 23140382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
